Globus Medical reports Q1 2026 results on May 7 with short sellers quietly adding pressure and options markets turning more defensive than their recent norm.
The most notable shift in positioning is the steady climb in short interest. It has risen nearly 10% over the past month to 3.2% of the free float — not an extreme level in absolute terms, but the direction is clear, with shorts adding roughly 7% more exposure week-on-week. The ORTEX short score has crept up to 35.6 from 32.9 just two weeks ago, tracking that incremental build. Borrow conditions remain loose — cost to borrow is just 0.40% and availability is ample — so this isn't a crowded or constrained short trade. It looks more like measured pre-earnings hedging than a conviction squeeze play.
Options positioning has tilted more cautious in the final days before the print. The put/call ratio moved up to 0.48, roughly 1.3 standard deviations above its 20-day average of 0.41. That's not at the year's most defensive extreme — the 52-week high is 0.70 — but the shift over the past week is visible. The stock itself has given back a little, slipping 0.6% on the day and 0.8% on the week, though it is still up 2.4% over the past month, closing at $90.03.
The Street remains firmly in the bull camp. Six buy-rated analysts cover the stock, with a consensus mean target of $110.08 — roughly 22% above the current price. The most recent analyst activity, from late February, was uniformly constructive: Wells Fargo, Barclays, and Needham all raised targets following the prior print, with Barclays sitting at the high end at $123. The bull case centres on Globus's 15-year track record in musculoskeletal devices, strong free-cash-flow potential, and continued integration upside from its spine and interventional pain acquisitions. Bears point to a possible slowdown in spine market growth, revenue disruption from the merger rebuild, and a valuation that leaves little room for margin disappointment — a bear-case target of $84 implies roughly 18x 2027 earnings, well below the current EV/EBITDA of 10.8x. EPS momentum ranks in the 73rd percentile on a 90-day basis, suggesting estimate revisions have been constructive, though the 30-day read is a more neutral 49th percentile.
Insider activity in recent months has been entirely one-directional: CFO Kyle Kline and General Counsel Kelly Huller both sold shares in early 2026, following a cluster of director sales late last year. Net insider value sold across the past 90 days reached roughly $5.4 million. None of the trades carry high significance scores, and they follow a period of strong price appreciation, so they read more as routine profit-taking than a signal of concern. The more notable institutional angle is Invesco's addition of roughly 2.9 million shares as of March 31 — a meaningful new position — while Sculptor trimmed half a million shares.
The earnings report will test whether Globus can demonstrate that its integration progress is translating into revenue momentum and margin expansion, rather than the dis-synergy drag that the bear case warns about.
See the live data behind this article on ORTEX.
Open GMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
